Former Apple and Intel Executive Michael Bell Joins Chemify as Chief Technology Officer

Contributed by: Business Wire

Logo

Business Wire logo

Images

Chemify, a deep tech chemical science company combining chemistry, robotics and AI at scale to digitally design, discover and make new molecules, announced today that Michael Bell has joined as Chief Technology Officer. As a well-known technology veteran in the digital computing industry who helped lead the creation of the Apple iPhone and the launch of Intel’s mobile devices, Mr. Bell will help accelerate the capabilities of Chemify’s digital chemistry platform and the world’s first chemical programming language. (Photo: Business Wire)
Chemify, a deep tech chemical science company combining chemistry, robotics and AI at scale to digitally design, discover and make new molecules, announced today that Michael Bell has joined as Chief Technology Officer. As a well-known technology veteran in the digital computing industry who helped lead the creation of the Apple iPhone and the launch of Intel’s mobile devices, Mr. Bell will help accelerate the capabilities of Chemify’s digital chemistry platform and the world’s first chemical programming language. (Photo: Business Wire)
Business Wire embedded0

Tags

Research
Professional Services
Pharmaceutical
Robotics
Technology
Artificial Intelligence
Health Technology
Science
Chemicals/Plastics
Biotechnology
Finance
Health
Manufacturing
chemical science

More Like This

Chemify, a deep tech chemical science company combining chemistry, robotics and AI at scale to digitally design, discover and make new molecules, announced today that Dr. Alastair Leighton has joined as Chief Operating Officer (COO). With almost three decades in the biopharma industry working at leading global pharmaceutical companies, Dr. Leighton brings a wealth of experience in manufacturing, supply chain operations and commercial strategy. (Photo: Business Wire)

Chemify Hires Biopharma Veteran Dr. Alastair Leighton as Chief Operating Officer

Prepaire Labs is a pioneering healthcare technology company focused on revolutionizing drug discovery and precision medicine. Through the integration of deep learning and biology, Prepaire Labs builds predictive models grounded in genetic, phenotypic, and clinical data. These models form a view to the underlying architecture and biology of diseases. Prepaire Labs utilizes patient-derived induced pluripotent stem cells (iPSCs), genome editing, high-content cellular phenotyping, and machine learning to create in vitro disease models for increased predictability of human clinical outcomes. A state-of-the-art BSL3 lab is opening in May 2024, located at Masdar City, Abu Dhabi, UAE. This will serve as the new fully automated LAAS (Lab As A Service) hub and provide clinical trials on a chip using latest microfluidic devices combined with the ability to print organoid bio-networks. Visit www.prepaire.com to learn more. (Photo: Business Wire)

Chemify Partners with Prepaire Labs to Apply Ground-breaking Chemistry AI-Robotics to Radically Accelerate the Discovery of Non-Addictive Opioids

PR Newswire associated0

ChemAI: AI-Driven Digital Chemistry Pioneer announces Strategic Rebrand and Key Board Appointments

Asymchem is pleased to announce Dr. Cheng Yi Chen has joined Asymchem as Small-Molecule Sector CTO. (Photo: Business Wire)

Asymchem Appoints Dr. Cheng Yi Chen as CTO of Small-Molecule Sector

PR Newswire associated0

Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer

BenevolentAI Appoints New Chief Technology Officer

Biosynth to Offer Complex Chemistry Solutions at Greater Scales Following Acquisition of VIO Chemicals

PR Newswire associated0

Wheeler Bio Appoints Industry Veteran Patrick Lucy as Chief Executive Officer